- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Breast-Specific Gamma Imaging Effective For All Breast Densities
Breast-specific gamma imaging detects breast cancer in both dense and nondense breast tissue.
Breast-specific gamma imaging (BSGI) is highly sensitive for detecting breast cancer in women with either dense or nondense breasts, according to a study published in the American Journal of Roentgenology.
Researchers from The George Washington University, in Washington, D.C., undertook a retrospective study of 341 women who had been diagnosed with breast cancer from January 2004 to August 2009 and who had undergone BSGI before surgical excision.
Women with predominantly fatty replaced (BI-RADS density 1) or scattered fibroglandular tissue (BI-RADS density 2) breasts were classified as nondense, and those with heterogeneously dense (BI-RADS density 3) or extremely dense tissue (BIRADS density 4) were classified as dense.
The results showed that overall sensitivity of BSGI for breast cancer detection was 95.4 percent. Positive BSGI examinations were present in 136 of 142 nondense breast cancers and 195 of 205 dense breast cancers, for sensitivities of 95.8 percent and 95.1 percent, respectively. There was no significant difference in BSGI breast cancer detection and parenchymal breast density.
“BSGI has high sensitivities for the detection of breast cancer in women with dense and nondense breasts and is an effective adjunct imaging modality in women with both dense and nondense breasts,” the authors concluded.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
